Tumor-specific mutations in low-frequency genes affect their functional properties by Erdem-Eraslan, L. (Lale) et al.
LABORATORY INVESTIGATION
Tumor-specific mutations in low-frequency genes affect their
functional properties
Lale Erdem-Eraslan • Daphne Heijsman • Maurice de Wit • Andreas Kremer •
Andrea Sacchetti • Peter J. van der Spek • Peter A. E. Sillevis Smitt •
Pim J. French
Received: 1 October 2014 / Accepted: 1 February 2015 / Published online: 19 February 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Causal genetic changes in oligodendrogliomas
(OD) with 1p/19q co-deletion include mutations in IDH1,
IDH2, CIC, FUBP1, TERT promoter and NOTCH1.
However, it is generally assumed that more somatic
mutations are required for tumorigenesis. This study aimed
to establish whether genes mutated at low frequency can be
involved in OD initiation and/or progression. We per-
formed whole-genome sequencing on three anaplastic ODs
with 1p/19q co-deletion. To estimate mutation frequency,
we performed targeted resequencing on an additional 39
ODs. Whole-genome sequencing identified a total of 55
coding mutations (range 8–32 mutations per tumor),
including known abnormalities in IDH1, IDH2, CIC and
FUBP1. We also identified mutations in genes, most of
which were previously not implicated in ODs. Targeted
resequencing on 39 additional ODs confirmed that these
genes are mutated at low frequency. Most of the mutations
identified were predicted to have a deleterious functional
effect. Functional analysis on a subset of these genes (e.g.
NTN4 and MAGEH1) showed that the mutation affects the
subcellular localization of the protein (n = 2/12). In
addition, HOG cells stably expressing mutant GDI1 or
XPO7 showed altered cell proliferation compared to those
expressing wildtype constructs. Similarly, HOG cells
expressing mutant SASH3 or GDI1 showed altered migra-
tion. The significantly higher rate of predicted deleterious
mutations, the changes in subcellular localization and the
effects on proliferation and/or migration indicate that many
of these genes functionally may contribute to gliomagen-
esis and/or progression. These low-frequency genes and
their affected pathways may provide new treatment targets
for this tumor type.
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Introduction
Oligodendrogliomas (ODs) account for 20 % of all glial
tumors and are thought to arise from oligodendroglial
precursor cells (OPCs). They are classified as either grade
II or grade III and have a more favorable clinical and
prognostic outcome with respect to other gliomas [1].
Frequently occurring driver mutations in oligoden-
drogliomas include mutations in IDH1, CIC, FUBP1,
TERT promoter and NOTCH [2–6]. However, tumor for-
mation is assumed to require more somatic mutations [7].
Interestingly, many other somatic mutations within protein-
coding genes have also been identified in oligoden-
drogliomas, albeit at a low frequency [8]. The role of most
of these infrequent mutations in tumorigenesis and/or
progression is unclear. To date, only few studies have
suggested a functional impact of genes mutated at low
frequency in gliomas [9–13]. Therefore, low-frequency
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genes that play a role in the initiation and/or progression of
ODs need to be identified to better understand OD patho-
genesis and for development of targeted therapies.
Here, we have performed whole-genome sequencing on
three ODs to identify all genetic changes in these tumors.
We then performed targeted resequencing on an additional
39 tumors to demonstrate that many of these mutations
occur at low frequency. Functional analysis of a subset of
these low-frequency genes (NTN4, GDI1, MAGEH1,
SASH3, ZNF238, OR5D14, ZNF57, DCUN1D2, ARSE,
XPO7, GABRE and PGLYRP4) suggest that they can
contribute to tumor pathogenesis and therefore are unlikely
to be passengers. These genes and their affected pathways
open up entirely novel treatment targets for this tumor type.
Materials and methods
Patient material
OD samples were collected from the Erasmus MC tumor
archive. Use of patient material was approved by the
Institutional Review Board and patients provided written
informed consent according to national and local regula-
tions for the clinical study and correlative tissue studies.
After surgical resection, all samples were snap-frozen and
stored at -80 C. Non-neoplastic DNA was isolated from
blood and stored at -80. Assessment of 1p19q LOH was
performed previously [14, 15]. Patient characteristics are
listed in supplementary Table 1.
DNA extraction and sequencing
Tumor DNA was extracted from fresh frozen (FF) tumor
samples using the AllPrep DNA/RNA mini kit (Qiagen,
Venlo, the Netherlands). Matched normal DNA was iso-
lated from 1 ml blood as part of routine diagnostic proce-
dures. Whole-genome sequencing was performed by
Complete Genomics (Mountain View, US) using 5 lg
DNA. Whole-genome sequencing data analysis was per-
formed using cgatools version 1.4.0 and described in sup-
plementary methods. All mutations were validated by
Sanger sequencing. Targeted resequencing on an additional
39 ODs was performed by Baseclear (Leiden, the Nether-
lands). Library construction and resequencing data analysis
were described in supplementary methods.
Cell lines and sorting
Constructs of wildtype and mutated genes were generated
by site directed mutagenesis (n = 12), and C-terminally
fused to GFP for visualization. Subsequently, Human oli-
godendroglial (HOG) cells [16] and HEK 293 cells were
transiently transfected with wildtype or mutant constructs
using lipofectamine according to the manufacturer’s
instructions. Stably transfected HOG cells were created as
described in supplementary methods.
Functional analysis
For proliferation experiments, cells (50.000 cells/well)
were plated in a 24-well Greiner plate (Greiner Bio-One,
Alphen a/d Rijn, the Netherlands) and followed using an
Incucyte (Essenbioscience, Hertfordshire, United King-
dom). Growth curves were constructed using the Con-
fluence v1.5 metric of the Incucyte software.
For migration experiments, cells were grown to con-
fluence in a 24-well Essen ImageLockplate after which a
cell-free zone (scratch) was created using a WoundMaker.
Wells were then washed in PBS after which serum-free
media was added to the plates. All plates were followed for
5 days and images were automatically captured at 3-h
intervals from 3 to 4 separate regions within a well.
Relative wound density, wound width and wound con-
fluency curves were constructed using data points of every
capture. All proliferation and migration experiments were
performed at least in triplicate.
Flow cytometric cell cycle analysis using propidium
iodide was performed as described in supplementary
methods.
Results
Whole-genome sequencing
To identify somatic alterations in oligodendrogliomas, we
performed whole-genome sequencing on DNA of three
ODs and their matched germline DNA. All tumors were
WHO grade III and had 1p19q co-deletion. The mapped
sequence of the six samples varied between 237 and
249 Gb, resulting in a coverage between respectively 83
and 90-fold per genome. Confident diploid calls could be
made for 94–95 % of the reference genome. On average
3,5 million genetic variants were identified per sample. Of
these, 55 (range of 8–32 variants per sample), were loca-
lized to coding exons, were neither synonymous nor pre-
sent in dbSNP130 and had a somatic score [-20 (see
supplementary methods) (Fig. 1). Identified variants con-
sisted of missense (84 %), nonsense (9 %) and frameshifts
(7 %). All 55 mutations were validated by Sanger
sequencing (supplementary Table 2).
We performed an in silico analysis on all 55 genes to
estimate the effect of mutation on protein. Polyphen-2
predictions were available for 43 genes of which 22 were
probably damaging, 9 possible damaging, and 12 were
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benign. In randomly picked mutations identified with a
lower confidence score (i.e. somatic scores B-20) the rate
of damaging mutations was significantly lower: 10 prob-
ably damaging, 8 possible damaging and 21 benign chan-
ges, (p = 0.033, Chi square test). The identified mutations
also had a slight tendency towards a higher conservation
compared to mutations with somatic scores B-20: GERP-
score 2.71 ± 2.96 v 1.75 ± 3.61 p = 0.156). The 55
mutations identified by whole-genome sequencing there-
fore were often predicted to have deleterious effects on the
protein.
Targeted resequencing
Because we aimed to determine functional effects of genes
mutated at low frequency in gliomas, we performed tar-
geted resequencing of 44 (of the 55 identified by whole-
genome sequencing) genes that were thusfar not implicated
in gliomagenesis (supplementary Table 2). Resequencing
was performed on the entire coding region of the 44 genes
on 39 grade II/III ODs of which 28/39 had 1p/19q LOH,
5/39 had loss of 1p or 19q and 6/39 had no 1p19q loss. We
chose this dataset because it represents a typical cohort of
histologically diagnosed oligodendrogliomas where most
will have 1p19q co-deletion, but some have other, more
aggressive genetic changes.
No mutations were found in 39 of the 44 genes in any of
the additional 39 tumors. Of the remaining five genes,
mutations were identified in only one additional sample
(Fig. 2, supplementary Table 4). In our samples, the
mutations were all present at a high allele frequency (range
39–84 %) suggesting that the mutation is present in a large
proportion of the resected tumor, at least within the tissue
investigated. Among the 28 tumors with 1p19q co-deletion,
mutations in only three of the 44 genes were identified
(supplementary Table 5). Although in individual tumors the
allele frequency was high, the overall mutation frequency of
all 44 genes was low. The mutations in the 44 genes
identified by our screen therefore are ‘low-frequency
genes’: genes mutated at low frequency in
oligodendrogliomas.
Apart from these low-frequency genes, we included a set
of known cancer genes (IDH1, IDH2, PTEN, TP53,
NOTCH1, EGFR, CDKN2A, CDKN2B, NF1 and PIK3R1)
for reference on our targeted resequencing effort. Analysis
of these known cancer-relevant genes revealed a total of 48
mutations (range of 1–4 mutations per tumor), which
consisted of missense (44) and nonsense (4) variants. These
include mutations in IDH1 (34 mutations in 39 tumors),
TP53 (4/39), NOTCH1 (3/39), EGFR (2/39), IDH2 (1/39),
CDKN2A (1/39), NF1 (1/39), PIK3R1 (1/39) and PTEN (1/
39) (Fig. 2, supplementary Table 4). Mutations in EGFR,
CDKN2A and PTEN were only found in patients with intact
1p19q chromosomes. Targeted resequencing therefore
confirmed a high frequency of mutations in genes that drive
oligodendrogliomas.
To better determine the incidence of the identified muta-
tions, we analyzed exome sequencing data of 7 oligoden-
drogliomas from Bettegowda et al. [2], 16 oligodendrogliomas
from Yip et al. [5] and 170 low-grade gliomas (LGG) and 290
glioblastomas (GBM) [8] from the TCGA dataset. In this
large dataset, most [36/44] mutations identified by whole-
genome sequencing that thus far are not implicated in oligo-
dendrogliomas, were also identified in one of these datasets;
eight were uniquely identified by us. The frequency was
however low: often only one sample was identified in the
external datasets with a mutation in that gene (supplementary
Fig. 1).
Mutations in low-frequency genes can affect
the proteins’ subcellular localization
In order to determine whether these low-frequency genes
may be involved in glioma pathogenesis, we performed a
more detailed molecular analysis on 12/44 of those genes
(Figs. 3, 4, 5). These 12 genes were randomly picked from
Fig. 1 Somatic genetic alterations in three oligodendrogliomas
identified by whole-genome sequencing. Shown are all mutations
identified in three tumors that (i) were localized to the coding regions
of exons,( ii) were nonsynonymous, (iii) were absent from dbSNP130
and (iv) had a somatic score[-20. Alterations are coded in greyscale
by the type of mutation (deletion, insertion, snp, substitution). The
number of alterations range from 8 to 32 variants per sample. All 55
mutations were validated by Sanger sequencing
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the 44 low-frequency genes. Transient transfection re-
vealed that in 2/12 constructs, the mutation affects the
proteins’ subcellular localization. In the gene NTN4, the
mutation resulted in a strong nuclear localization, which
was absent in the wildtype (Fig. 3). For MAGEH1, the
mutation resulted in a reduced or even absent nuclear lo-
calization. No differences in the subcellular localization
between wildtype and mutant constructs were found in
cells expressing GDI1, ZNF238, SASH3, XPO7, ZNF57,
GABRE, OR5D14, PGLYRP4, ARSE and DCUN1D2 (not
shown).
Low-frequency genes can affect proliferation and/
or migration
To further examine the functional properties of low-frequency
genes, we generated cell lines stably expressing the mutant or
wildtype variant of four genes and performed functional
analysis on proliferation and migration (Figs. 4, 5).
The first gene examined was GDI1, in which the
mutation was located in the geranyl–geranyl transferase
domain (c.577C[T, p.R193C). HOG cells stably
expressing wildtype GDI1 have increased proliferation
compared to those expressing GDI1R193C or eGFP (p =
0.003, p = 0.04, respectively, n = 2). This is also con-
firmed by flow cytometry, showing that in cells expressing
wildtype GDI1, 7.5 % more cells are found in the S-G2-M
phase and 8.5 % less in the G1 compared to those
expressing GDI1R193C (supplementary Fig. 2). No differ-
ences in proliferation were observed between GDI1R193C
and eGFP cells (p = 0.7). Similarly, HOG cells stably
expressing GDI1 wildtype showed increased migration
compared to GDI1R193C or eGFP (p = 0.003, p = 0.0005
respectively, n = 2). No differences in migration were
observed between GDI1R193C and eGFP cells (p = 0.3).
The differences in both proliferation and migration
between wildtype and mutant constructs indicate that the
mutation in GDI1 affects the functional property of the
protein.
Our second gene examined was XPO7, in which a
mutation was identified in the ARM-type fold domain
(c.709G[A, p.D237N). An increase in proliferation was
observed during the first 24 h in cells stably expressing
XPO7D237N compared to wildtype and eGFP cells
(p = 0.02, p\ 0.001 (n = 2), respectively). After 24 h,
the proliferation rate was similar in cells stably expressing
wildtype, XPO7D237N and eGFP. Because of the differ-
ences in proliferation at the start of the experiment,
XPO7D237N cells reach confluency more rapid than wild-
type or eGFP cells. The initial difference was consistently
observed in multiple experiments with 3–6 wells per
experiment and 4 positions per well. Because cells were
plated at 2 different densities (50.000 and 100.000 cells per
well) the observed difference in initial proliferation rates
appeared independent of plating density. A possible
Fig. 2 Targeted resequencing on 39 ODs confirms that many genes
are mutated at low frequency. Of the known cancer genes (IDH1/2,
TP53, NOTCH1, EGFR, CDKN2A, NF1, PIK3R1 and PTEN), a total
of 48 mutations (range 1–4 mutations per tumor) were identified in 39
tumors (known causal cancer genes). Of the genes identified by
whole-genome sequencing that thus far are not implicated in
oligodendrogliomas, no mutations were found in 39 of the 44 genes
in any of the additional 39 tumors (not shown). In the remaining five
genes, we identified mutations in only one additional sample
(indicated in the figure as low-frequency genes). Distribution of
1p19q status is reported for each identified mutation. Mutations in
EGFR, CDKN2A and PTEN were only found in patients with intact
1p19q status
cFig. 3 Mutations in low-frequency genes can affect the subcellular
localization of proteins. HOG and HEK 293 cells were transiently
transfected with either the wildtype or mutant construct and stained
for GFP (green), DAPI (blue) and Alexa fluor phalloidin (red). A total
of twelve wildtype and mutant construct pairs were made. In both cell
lines, the mutated NTN4 construct showed a stronger nuclear staining
pattern compared to the wildtype construct. For MAGEH1, the
mutation resulted in a reduced or even absent nuclear staining. No
differences in the subcellular localization between wildtype and
mutant constructs were found in HOG and HEK 293 cells expressing
GDI1, ZNF238, SASH3, XPO7, ZNF57, GABRE, OR5D14,
PGLYRP4, ARSE and DCUN1D2 (not shown)
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explanation for this difference is that XPO7D237N cells
recover more rapidly after plating. Migration of cells
expressing XPO7D237N or wildtype was higher than those
expressing eGFP (p = 0.05, p = 0.03, respectively
(n = 2)). No differences in migration were observed
between cells expressing XPO7D237N and wildtype
(p = 0.5). The effect of the identified point mutation in
XPO7 on proliferation highlights its importance for protein
function in these cells.
The third gene examined was SASH3, in which the
mutation was located in the SAM domain (c.862C[T),
partially disrupting this domain in the C-terminal region
(p.R288*). HOG cells stably expressing SASH3 wildtype,
SASH3R288* or eGFP have a similar proliferation rate
(n = 3). However, cells expressing wildtype SASH3, show
increased migration compared to SASH3R288* or eGFP. The
difference in migration between wildtype and
SASH3R288*indicates that the mutation affects the function
of the wildtype protein (p = 0.001, n = 2).
Our last gene examined was ZNF238, in which the muta-
tion was located in a BTB/POZ fold domain (c.361G[A,
p.V121I). In HOG cells stably expressing ZNF238 wildtype
or ZNF238V121I constructs, we observed a slight decrease in
proliferation compared to eGFP expressing cells (p\ 0.001,
n = 4).Amore pronounced effectwas observed inmigration:
HOG cells stably expressing ZNF238 wildtype and
ZNF238V121I show a strong decrease compared to eGFP.
These results were consistently observed in multiple experi-
ments (p\ 0.001, n = 4). Although no differences were
observed between wildtype and mutant constructs, the results
do indicate that wildtype or ZNF238V121I constructs affect
cellular proliferation and migration.
Discussion
In this study, we have performed whole-genome and tar-
geted resequencing on 3 and 39 oligodendrogliomas to
Fig. 4 Mutations in low-frequency genes can affect cell growth.
a HOG cells stably expressing wildtype GDI1 show increased
proliferation compared to GDI1R193C expressing cells (p = 0.003,
n = 2 independent experiments). b Cells stably expressing
XPO7D237N show a higher rate of proliferation during the first 24 h,
compared to wildtype expressing cells (p = 0.02, (n = 2)). After
24 h, similar proliferation rates were observed in wildtype and
XPO7D237N. c HOG cells stably expressing SASH3 wildtype or
SASH3R288* and d wildtype or ZNF238V121I show similar prolifera-
tion rates (n = 3)
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identify somatic mutations. Apart from the known fre-
quently mutated genes such as IDH1, CIC and FUBP1, our
study also identified genes that were infrequently mutated
(i.e. in one or two samples only). Most low-frequency genes
are predicted to affect the protein’s function by in silico
analysis. A significantly higher proportion of genes had a
potential deleterious effect compared to mutations in genes
identified with a lower confidence score (i.e. somatic scores
B-20). Functional analysis of these low-frequency genes
indicated that the identified mutation can affect protein
subcellular localization and/or cell physiology. Our results
therefore suggest that (at least some of) these genes may be
relevant for gliomagenesis and/or contribute to progression.
The frequency of mutations identified at a higher fre-
quency in our study (IDH1, CIC and FUBP1) are similar to
those reported by others for this tumor type. Mutations in
the ATRX gene were not identified; this gene is frequently
mutated in other glioma subtypes including WHO grade II-
III astrocytomas (71 %), oligoastrocytomas (68 %) and
secondary glioblastomas (57 %) [2, 5]. Also similar to
reported by others, mutations in EGFR, CDKN2A and PTEN
were mutually exclusive with 1p19q co-deletion [2–5, 8].
To our knowledge, our study is the first to functionally
study low-frequency genes on a larger scale. Several other
studies have demonstrated a functional impact of genes
mutated at a low frequency [9–13, 17]. Our data therefore
are in line with the hypothesis that genes mutated at low
frequency in gliomas can functionally contribute to
gliomagenesis.
Of the genes examined, the mutations identified in NTN4
and MAGEH1 were predicted as ‘‘probably damaging’’ by
Polyphen-2 analysis and affected the protein subcellular
localization. Both mutations in NTN4 and MAGEH1 are not
located in any of the known signal peptides for protein lo-
calization . These mutations may affect protein folding and
sorting, however this would be accompanied by an accu-
mulation of proteins in the ER, and we did not observe such
accumulation in our transfected cells.
Of the genes examined in more detail, the mutation
identified in GDI1 was predicted as ‘‘probably damaging’’
Fig. 5 Mutations in low-frequency genes can affect cell migration.
a HOG cells stably expressing GDI1 wildtype have a higher migration
rate compared to GDI1R193C expressing cells (p = 0.003, n = 2
independent experiments). b No differences in migration were
observed between cells expressing wildtype and XPO7D237N or
between cells expressing ZNF238 wildtype and mutant (d) (p = 0.5).
c Cells expressing wildtype SASH3, show increased migration
compared to SASH3R288*(p = 0.039)
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by Polyphen-2 analysis and did not affect the protein sub-
cellular localization. Our data show that HOG cells stably
expressing wildtype GDI1 have increased proliferation and
migration compared to those expressing GDI1R193C or
eGFP. The proliferation experiments were validated by flow
cytometry, showing that wildtype GDI1 expressing cells are
more present in the S-G2-M phase and less in the G1
compared to mutant GDI1 expressing cells. GDI1 encodes
for GDP dissociation inhibitor 1, which is involved in re-
cycling of Rab proteins and contains a GTPase activation
GDI1-b2/GDI1-b and geranyl–geranyl transferase domain
(supplementary Fig. 3) [18–20]. The GTPase activating
domain of GDI1 interacts with the GDP-bound Rab pro-
teins, while the geranyl–geranyl domain interacts with the
prenylated binding motif of Rab protein [21].
The altered migration may be caused by a differential
activation of Rab proteins by GDI. Rab proteins belong to
the Ras superfamily and are involved in vesicle trafficking
between cellular compartments along actin or microtubules
[22]. Binding of GDI to prenylated GDP-bound Rab pro-
tein in the cytosol mediates the delivery of Rab proteins to
membranes during vesicle formation and their return into
the cytosol after vesicle fusion [23, 24]. Importantly, Rab
proteins seem to direct migration of cancer cells by reg-
ulating integrin recycling [25]. This mutation is function-
ally important as mutated GDI1 does not stimulate cell
proliferation and migration whereas wildtype GDI1 does.
The second gene examined was XPO7, in which the
mutation was also predicted to be probably damaging by
Polyphen-2 analysis. The mutation did not affect the pro-
tein subcellular localization. Our data indicate that both
wildtype and XPO7 D237N increase the proliferation rate of
HOG cells. XPO7 encodes for exportin 7, which is a
nuclear transport receptor that exports cargos from the
nucleus into the cytoplasm [26]. This protein contains a
N-terminal Importin-beta domain that binds to RAN and an
ARM-type fold domain [26]. Its C-terminal region is
thought to be involved in the recognition of substrates with
broad specificity [27]. The fact that both wildtype and
XPO7 D237N stimulate cell proliferation and migration,
highlights the importance of this gene.
The third gene examined was SASH3, in which the
mutation was predicted as probably damaging by Poly-
phen-2 analysis and did not affect the protein subcellular
localization. The current study found that cells expressing
wildtype SASH3, but not SASH3R288*, show increased
migration, indicating that the mutation affects the function
of the wildtype protein. SASH3 encodes a signaling adapter
protein, containing a SLY motif in the N-terminal region, a
SH3 motif and a SAM motif in the C-terminal region [28].
SAM families of receptors are known to play a role in
many developmental processes including cell migration,
neuronal formation and angiogenesis [28]. They seem to
mediate signal transduction by connecting downstream
effector proteins to cell surface receptors [29, 30]. The
altered migration pattern in SASH3R288* expressing cells
may therefore be caused by disturbed signal transduction
pathways that lead to cell migration. This mutation is
functionally important as SASH3R288* does not stimulate
cell migration where wildtype SASH3 does.
The last gene examined was ZNF238, in which the
mutation was predicted as ‘‘probably damaging’’ by Poly-
phen-2 analysis and did not affect the protein subcellular
localization. Our data indicate that cells stably expressing
wildtype or ZNF238V121I decrease proliferation and mi-
gration compared to control. The present finding is con-
sistent with other studies in which ZNF238 was found to
decrease proliferation [31, 32] and that ZNF238 is essential
for neuronal migration in experimental mouse models [32–
34]. ZNF238 encodes a transcriptional repressor that con-
tains a BTB/POZ fold domain in the N-terminal region and
four zinc fingers in the C-terminal region [35, 36]. This
protein family plays a role in many processes, including
DNA damage response, cell cycle and developmental
processes [31–34, 37]. Our observation that wildtype and
mutant constructs affect cellular proliferation and migra-
tion, highlights the important role of this gene.
Although our data argue that many genes are function-
ally relevant for gliomas, there are some limitations to our
study. For all functional experiments, we have only utilized
the HOG cell line, as these cells have been well charac-
terized and resemble immature oligodendrocytes [16].
Whether these effects are retained in other cell lines re-
mains to be determined. For example, to determine whether
these genes indeed contribute to gliomagenesis, similar
experiments need to be performed in stem cells, patient
derived xenografts and various in vivo experiments.
However because mutations occur at such low frequency,
patient-derived primary cultured tumor cell lines contain-
ing these mutations are hard to obtain. Moreover, oligo-
dendrogliomas with 1p19qLOH and/or IDH1 mutated
tumors virtually cannot be propagated in vitro. Never-
theless, our data shows that even in a single cell line, a
substantial proportion of low-frequency genes functionally
affects cell physiology.
Another limitation of this study is that we have only
performed functional analysis of a few genes. However, in
a substantial proportion of the examined genes, the muta-
tion affected the function of the wildtype protein. Our data
therefore suggest that a substantial proportion of low-fre-
quency genes are functionally relevant for glioma initiation
and/or progression.
In contrast to may be expected for oncogenic mutations,
we found that the proliferation and/or migration rate was
reduced in cells expressing GDI1 R1193C, ZNF238V121I and
SASH3R288*. It is not uncommon for ectopic expression of
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oncogenes in various cell lines to result in reduced pro-
liferation and altered migration. In fact, Sun et al. have
shown that expression of EGFR in mutant melanoma cells
confers a growth disadvantage that is further strengthened
by the addition of EGFR ligand [38]. A similar growth
disadvantage (and altered migration pattern) was observed
when expressing IDH1R132H [10, 39]. Perhaps, this is a
relatively common physiological response of cells that
have never been dependent on a specific oncogene. It is
however also possible that the mutation does not contribute
to tumor formation/progression but simply has deleterious
effects on the functioning of the wildtype protein.
In conclusion, we have demonstrated that low-frequency
genes can affect the proteins’ subcellular localization and/
or physiology in HOG cells. These findings indicate that
low-frequency genes functionally can contribute to
gliomagenesis and/or progression and suggest these genes
as new therapeutic targets for treatment for this tumor type.
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